Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ePoster Display

1169TiP - Penpulimab-based combination neoadjuvant/adjuvant therapy for patients with resectable locally advanced non-small cell lung cancer: A phase II clinical study (ALTER-L043)

Date

16 Sep 2021

Session

ePoster Display

Presenters

Changli Wang

Citation

Annals of Oncology (2021) 32 (suppl_5): S931-S938. 10.1016/annonc/annonc727

Authors

C. Wang1, M. Wang1, B. Yu2

Author affiliations

  • 1 Lung Oncology, Tianjin Medical University Cancer Institute & Hospital, 300011 - Tianjin/CN
  • 2 Thoracic Surgery, The First Affiliated Hospital of Nanchang University, 330006 - Nanchang/CN
More

Abstract 1169TiP

Background

Immunotherapy alone or combined with chemotherapy as neoadjuvant therapy has shown encouraging results. Penpulimab, a human IgG1 monoclonal antibody directed against human programmed cell death-1 (PD-1), was engineered to eliminate Fc-mediated effector function that compromises anti-tumor immune cell function, and to optimize receptor occupancy by improving duration of drug binding. As a promising multi-target tyrosine kinase inhibitor, Anlotinib significantly improved overall survival in advanced NSCLC patients in the phase III trial ALTER0303. Antiangiogenesis therapy combined with PD-1/PD-L1 inhibitors has shown excellent efficacy in advanced non-small cell lung cancer (NSCLC) patients. This is the trial evaluating Penpulimab combined with Anlotinib or chemotherapy or both of them as neoadjuvant/adjuvant therapy for patients with resectable locally advanced NSCLC.

Trial design

This is a multicenter, randomized, open-label, phase II study (NCT04846634). Eligible patients were 18-70 years old with measurable, pathologically confirmed stage IIB-IIIB (N2) NSCLC patients with negative driver gene mutation. Other key inclusion criteria included ECOG PS of 0-1, adequate organ function and sufficient lung function for the intended lobectomy or pneumonectomy. Patients were randomized to receive either Penpulimab (200mg, iv, Q3W) plus platinum based chemotherapy or Penpulimab (200mg, iv, Q3W) plus Anlotinib (12mg, po, day 1-14, Q3W) or Penpulimab (200mg, iv, Q3W) plus platinum based chemotherapy and Anlotinib (12mg, po, day 1-14, Q3W) in a 1:1:1 ratio. The primary outcome was major pathological response (MPR) rate, the secondary outcomes were objective response rate (ORR), pathologic complete response (pCR), event-free survival (EFS), 1 year EFS rate, overall survival (OS) and safety.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Funding

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.